Uncategorized
Gemini Therapeutics Announces Presentation of Preclinical Data at the 13th International Conference on Complement Therapeutics
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced one oral presentation and the presentation of three posters at the 13th International Conference on Complement Therapeutics held in Ioannina, Greece from September 8-13, 2021. “The results presented today underscore the potential of GEM103 as the next class of comp